Chemo-free BRCA-targeted Neoadjuvant Strategy

Summary

This is a multicenter randomized phase ll clinical trial to evaluate the pathological complete response (pCR) in the tumour burden (primary and lymph nodes) with olaparib alone or in the olaparib and durvalumab arm in TNBC patients candidate for neoadjuvant strategy showing a t/gBRCAmut or BRCAness/HRD profile.

Timeline

Start

2024-02-01

Primary completion

2028-09-06

Completion

2030-07-18

Outcome

Outcome not reported

Stopped: “Withdrawn interest from grant provider”

Drugs

Indications